Genpharmasec Ltd

Genpharmasec Limited has submitted its Annual Report for the Financial Year 2025-26, along with the Notice of the 34th Annual General Meeting (AGM). The report details the audited standalone and consolidated financial statements for the year ended March 31, 2026. The AGM will be held on September 29, 2026, via video conferencing to adopt these financial statements and appoint a director. The company is distributing the report electronically to members with registered email addresses and providing a web-link for others. The Annual Report and AGM Notice are also available on the company's website.

Genpharmasec Ltd has issued a notice for its 34th Annual General Meeting (AGM) scheduled for September 29, 2026, at 11:00 AM IST. The meeting will be conducted via Video Conferencing/Other Audio-Visual Means. Key agenda items include the adoption of audited standalone and consolidated financial statements for the fiscal year 2025-26, the re-appointment of Mr. Sohan Chaturvedi as a director retiring by rotation, and his re-appointment as Whole-Time Director for a period of three years from April 26, 2027, to April 25, 2030. The AGM notice and explanatory statement are available on the company's website.

Genpharmasec Ltd announced the outcome of its Board of Directors meeting held on September 2, 2026. The board has fixed Tuesday, September 29, 2026, as the date for the 34th Annual General Meeting (AGM), to be conducted via Video Conferencing (VC) or Other Audio Visual Means (OAVM). The cut-off date for determining voting rights is set for Tuesday, September 22, 2026, with e-voting commencing on September 26 and concluding on September 28, 2026. Additionally, the board approved the Director's Report and Annual Report for the Financial Year 2025-26, along with the closure of the Share Transfer Book from September 23 to September 29, 2026. The appointment of M/S. Jaymin Modi & Co. as Scrutinizer for the AGM was also approved. Furthermore, the re-appointment of Mr. Sohan Chaturvedi as Whole Time Director, subject to shareholder approval, and approval for advances/loans/guarantees under Section 185 of the Companies Act, 2013, subject to shareholder approval, were considered and approved.

Genpharmasec Ltd announced outcomes of its Board of Directors meeting held on September 2, 2026. The board has fixed Tuesday, September 29, 2026, as the date for the 34th Annual General Meeting (AGM), to be conducted via Video Conferencing. Key decisions include approving the Director's Report and Annual Report for FY 2025-26, setting September 22, 2026, as the cut-off date for voting rights, and scheduling e-voting from September 26 to September 28, 2026. The company also approved the closure of Share Transfer Books from September 23 to September 29, 2026, for the AGM. Additionally, M/S. Jaymin Modi & Co. was appointed as the scrutinizer for the AGM, and Mr. Sohan Chaturvedi's re-appointment as Whole Time Director was approved, subject to shareholder consent.

Rajesh Sadhwani and Persons Acting in Concert (PACs) have acquired an additional 1.17% stake in Genpharmasec Limited through open market purchases. The acquisition, totaling 65,00,000 shares, brings their combined holding to 32.06% of the total share capital. The transactions occurred on August 31, 2026, and September 1, 2026. This disclosure is made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Rajesh Mirchumal Sadhwani, identified as part of the promoter/promoter group, has acquired an additional 0.90% stake in Genpharmasec Limited through open market purchases. This acquisition, executed on August 28, 2026, brings the total shareholding of Rajesh Sadhwani and his Person Acting in Concert (PAC), Sneha Sadhwani, to 30.88% of the total share capital. Prior to this transaction, their combined holding was 29.98%. The acquisition involved 50,00,000 equity shares.

Genpharmasec Ltd has announced a Board of Directors meeting scheduled for September 2, 2026. The primary agenda items include fixing the date, time, and mode for the 34th Annual General Meeting (AGM) for the fiscal year ended March 31, 2026. The board will also consider and approve the draft notice and calendar of events for the AGM, set the cut-off date for e-voting, approve the Directors' Report and the Annual Report for FY 2025-26, and approve the closure of share transfer books. Additionally, the appointment of a scrutinizer for the e-voting process at the AGM will be considered.

Genpharmasec Limited has entered into a non-exclusive Super Stockist agreement with Amneal Healthcare Private Limited (AHPL). Under this agreement, Genpharmasec will distribute AHPL's products to wholesale and retail pharmacists within a specified territory. AHPL has committed to a minimum annual sales target of approximately INR 75 Crores for Genpharmasec each calendar year during the term of the agreement. This partnership aims to expand Genpharmasec's market presence and distribution capabilities, offering a wider range of healthcare products to customers. Genpharmasec, established in 1992, shifted its focus to pharmaceutical distribution in 2018 and currently distributes diagnostic equipment. Amneal Pharmaceuticals, Inc. is a global leader in essential medicines with a significant investment in India.

Genpharmasec Ltd has filed a statement confirming no deviation or variation in the utilization of proceeds from its Rights Issue for the quarter ended June 30, 2026. The funds, amounting to ₹4,845.05 Lakhs raised on February 21, 2024, were allocated to acquiring equity shares in Derren Healthcare Private Limited, repaying borrowings, working capital, general corporate purposes, and issue expenses. The Audit Committee has reviewed the statement and found no comments. The company has utilized the funds as per the original objects stated in the Letter of Offer.

Genpharmasec Limited announced that its Board of Directors, in a meeting held on August 11, 2026, has considered and approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The results were reviewed by the Audit Committee and are accompanied by a Limited Review Report from the independent auditor, Bilimoria Mehta & Co. The board meeting commenced at 3:00 p.m. and concluded at 3:50 p.m. The company has submitted these results as per SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.